PROSPECTs Futile For Bavarian Nordic's Prostvac Cancer Vaccine
Executive Summary
The Phase III PROSPECT study's data monitoring committee decides against continuing after interim analysis. The fall-out could hit Bavarian Nordic’s CV301 too.
You may also be interested in...
Bavarian Nordic Transformed By GSK Vaccines Buy
Buying two vaccines for rabies and tick-borne encephalitis complements the recently approved smallpox and monkeypox vaccine Jynneos. Now the Danish firm needs to start selling them.
Monkeypox Vaccine Approval A Shot In The Arm For Bavarian
Nigeria's monkeypox outbreak represents opportunity for Danish company still looking to overcome cancer vaccine setback.
The Year's Clinical Trials In Review: Big Misses In 2017
The big clinical trial setbacks hurt. Scrip takes a look back at the painful clinical trial failures this year, with Axovant's intepirdine and Celgene's mongersen topping the list.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports